loading
Acadia Pharmaceuticals Inc stock is traded at $14.75, with a volume of 849.96K. It is up +0.89% in the last 24 hours and down -2.32% over the past month. Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
See More
Previous Close:
$14.62
Open:
$14.745
24h Volume:
849.96K
Relative Volume:
0.59
Market Cap:
$2.43B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
-16.03
EPS:
-0.92
Net Cash Flow:
$80.53M
1W Performance:
+0.07%
1M Performance:
-2.32%
6M Performance:
-13.49%
1Y Performance:
-38.72%
1-Day Range:
Value
$14.41
$14.80
1-Week Range:
Value
$14.41
$15.02
52-Week Range:
Value
$14.15
$32.59

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
Name
Acadia Pharmaceuticals Inc
Name
Phone
858-558-2871
Name
Address
12830 EL CAMINO REAL, SAN DIEGO
Name
Employee
690
Name
Twitter
@acadiapharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
ACAD's Discussions on Twitter

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-12-24 Downgrade Mizuho Buy → Neutral
Mar-12-24 Reiterated Needham Buy
Jan-30-24 Initiated Robert W. Baird Outperform
Jan-24-24 Upgrade Needham Hold → Buy
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-14-23 Downgrade Deutsche Bank Buy → Hold
Dec-13-23 Initiated Citigroup Buy
Dec-12-23 Initiated Deutsche Bank Buy
Nov-06-23 Upgrade Mizuho Neutral → Buy
Oct-17-23 Initiated UBS Buy
Oct-10-23 Upgrade JP Morgan Neutral → Overweight
Jan-03-23 Upgrade Guggenheim Neutral → Buy
Nov-04-22 Downgrade Goldman Neutral → Sell
Nov-01-22 Initiated Loop Capital Hold
Aug-08-22 Downgrade Citigroup Buy → Neutral
Aug-05-22 Downgrade Citigroup Buy → Neutral
Jun-21-22 Downgrade Jefferies Buy → Underperform
Jun-16-22 Upgrade Jefferies Hold → Buy
Mar-16-22 Upgrade Canaccord Genuity Hold → Buy
Feb-09-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-05-22 Upgrade Citigroup Neutral → Buy
Dec-21-21 Downgrade Guggenheim Buy → Neutral
Nov-01-21 Upgrade Guggenheim Neutral → Buy
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Jun-10-21 Initiated Berenberg Hold
Apr-07-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-06-21 Downgrade Canaccord Genuity Buy → Hold
Apr-06-21 Downgrade Goldman Buy → Neutral
Apr-06-21 Downgrade Jefferies Buy → Hold
Apr-06-21 Downgrade Mizuho Buy → Neutral
Apr-05-21 Downgrade Raymond James Outperform → Mkt Perform
Mar-10-21 Downgrade BofA Securities Buy → Neutral
Mar-09-21 Downgrade Citigroup Buy → Neutral
Mar-09-21 Downgrade Guggenheim Buy → Neutral
Mar-09-21 Reiterated H.C. Wainwright Buy
Mar-09-21 Downgrade Raymond James Strong Buy → Outperform
Mar-09-21 Downgrade Stifel Buy → Hold
Dec-16-20 Initiated Mizuho Buy
Nov-16-20 Upgrade Raymond James Outperform → Strong Buy
Aug-25-20 Initiated Raymond James Outperform
Aug-20-20 Initiated Morgan Stanley Overweight
Jul-07-20 Upgrade Stifel Hold → Buy
Apr-16-20 Initiated Jefferies Buy
Mar-31-20 Upgrade Goldman Neutral → Buy
Mar-06-20 Initiated Citigroup Buy
Dec-16-19 Initiated Guggenheim Buy
Oct-24-19 Initiated Oppenheimer Perform
Oct-01-19 Initiated RBC Capital Mkts Outperform
Sep-13-19 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-10-19 Upgrade Canaccord Genuity Hold → Buy
Jul-23-19 Reiterated Needham Buy
Dec-10-18 Initiated Canaccord Genuity Hold
Sep-21-18 Upgrade Piper Jaffray Neutral → Overweight
Aug-09-18 Reiterated Stifel Hold
Aug-07-18 Initiated Stifel Hold
Aug-06-18 Downgrade Piper Jaffray Overweight → Neutral
Oct-06-17 Resumed Goldman Neutral
View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

pulisher
08:08 AM

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by AlphaCentric Advisors LLC - MarketBeat

08:08 AM
pulisher
Oct 31, 2024

ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024 - Insider Monkey

Oct 31, 2024
pulisher
Oct 30, 2024

10 Worst-Performing Growth Stocks in 2024 - Insider Monkey

Oct 30, 2024
pulisher
Oct 30, 2024

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

ACADIA Pharmaceuticals (ACAD) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Emerging Insights: Market Trends in Multiple System Atrophy (MSA) Market | Acadia Pharmaceuticals Inc - EIN News

Oct 30, 2024
pulisher
Oct 24, 2024

ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE uptake lags By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 23, 2024

ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE uptake lags - Investing.com India

Oct 23, 2024
pulisher
Oct 23, 2024

ACADIA Pharmaceuticals stock hits 52-week low at $14.31 By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 23, 2024

ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 1-Year LowWhat's Next? - MarketBeat

Oct 23, 2024
pulisher
Oct 23, 2024

ACADIA Pharmaceuticals stock hits 52-week low at $14.31 - Investing.com India

Oct 23, 2024
pulisher
Oct 22, 2024

Parkinsons Disease Psychosis Market Forecasted to Surge - openPR

Oct 22, 2024
pulisher
Oct 21, 2024

Ryan Reynolds' Latest Film: 'More To Parkinson's' 08/19/2024 - MediaPost Communications

Oct 21, 2024
pulisher
Oct 19, 2024

(ACAD) Long Term Investment Analysis - Stock Traders Daily

Oct 19, 2024
pulisher
Oct 19, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 19, 2024
pulisher
Oct 18, 2024

Acadia's DAYBUE wins first Canada nod for Rett syndrome treatment By Investing.com - Investing.com Australia

Oct 18, 2024
pulisher
Oct 17, 2024

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 - BioSpace

Oct 17, 2024
pulisher
Oct 17, 2024

Equities Analysts Issue Forecasts for ACADIA Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ACAD) - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Health Canada approves Acadia’s DAYBUE for Rett syndrome - Pharmaceutical Technology

Oct 17, 2024
pulisher
Oct 16, 2024

Acadia's DAYBUE wins first Canada nod for Rett syndrome treatment - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Neuren announces that trofinetide has received marketing authorisation in Canada - Biotech Dispatch

Oct 16, 2024
pulisher
Oct 16, 2024

Acadia Pharmaceuticals Announces Health Canada Approval Of DAYBUE (Trofinetide) For The Treatment Of Rett Syndrome - XM

Oct 16, 2024
pulisher
Oct 16, 2024

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome - StockTitan

Oct 16, 2024
pulisher
Oct 15, 2024

Parkinsons Disease Therapeutics Market to Grow with Incredible - openPR

Oct 15, 2024
pulisher
Oct 14, 2024

Are ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Down 13.5% in September - MarketBeat

Oct 14, 2024
pulisher
Oct 14, 2024

Zacks Research Research Analysts Lift Earnings Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Oct 14, 2024
pulisher
Oct 10, 2024

Autism Spectrum Disorder Market, 2034 | Scioto Biosciences, - openPR

Oct 10, 2024
pulisher
Oct 10, 2024

ACADIA Pharmaceuticals (NASDAQ:ACAD) Receives "Market Perform" Rating from Raymond James - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know - Benzinga

Oct 10, 2024
pulisher
Oct 10, 2024

Sanctuary Advisors LLC Acquires Shares of 91,834 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Oct 10, 2024
pulisher
Oct 08, 2024

Long Term Trading Analysis for (ACAD) - Stock Traders Daily

Oct 08, 2024
pulisher
Oct 08, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 08, 2024
pulisher
Oct 08, 2024

ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year LowHere's What Happened - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Simply Wall St

Oct 08, 2024
pulisher
Oct 08, 2024

Healthcare of Ontario Pension Plan Trust Fund Decreases Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Inside Ryan Reynolds’ heartfelt Parkinson’s campaign - PR Week

Oct 08, 2024
pulisher
Oct 07, 2024

Dimensional Fund Advisors LP Buys Shares of 649,150 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

SG Americas Securities LLC Buys 417,648 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Oct 06, 2024
pulisher
Oct 05, 2024

The Manufacturers Life Insurance Company Reduces Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Schizophrenia Market Projected for Significant Growth by 2034: - openPR

Oct 04, 2024
pulisher
Oct 02, 2024

Glioblastoma Pipeline Trends 2024: Clinical Trials, - openPR

Oct 02, 2024
pulisher
Oct 01, 2024

Millennium Management LLC Has $47.74 Million Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Schizophrenia Market Forecasted to Surge in Coming Years, - openPR

Sep 30, 2024
pulisher
Sep 30, 2024

Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart

Sep 30, 2024
pulisher
Sep 29, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Update - MarketBeat

Sep 29, 2024
pulisher
Sep 29, 2024

Algert Global LLC Buys 179,799 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Sep 29, 2024
pulisher
Sep 28, 2024

Acadia replaces outgoing CEO with BMS exec - The Pharma Letter

Sep 28, 2024
pulisher
Sep 28, 2024

How to Take Advantage of moves in (ACAD) - Stock Traders Daily

Sep 28, 2024
pulisher
Sep 28, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Acquired by D. E. Shaw & Co. Inc. - MarketBeat

Sep 28, 2024
pulisher
Sep 28, 2024

Acadia Pharmaceuticals surges 32% after win in patent suit over Nuplazid (update) - MSN

Sep 28, 2024

Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):